KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Three quarter of endometrial carcinomas are treated at early stage. Still, 15 to 20% of these patients experience recurrence, with little effect from systemic therapies. Homo sapiens v-Ki-ras2 Kirsten rat sarcoma viral oncogenes homologue (KRAS) mutations have been reported to have an important role in tumorigenesis for human cancers, but there is limited knowledge regarding clinical relevance of KRAS status in endometrial carcinomas. METHODS: We have performed a comprehensive and integrated characterisation of genome-wide expression related to KRAS mutations and copy-number alterations in primary- and metastatic endometrial carcinoma lesions in relation to clinical and histopathological data. A primary investigation set and clinical validation set was applied, consisting of 414 primary tumours and 61 metastatic lesions totally. RESULTS: Amplification and gain of KRAS present in 3% of the primary lesions and 18% of metastatic lesions correlated significantly with poor outcome, high International Federation of Gynaecology and Obstetrics stage, non-endometrioid subtype, high grade, aneuploidy, receptor loss and high KRAS mRNA levels, also found to be associated with aggressive phenotype. In contrast, KRAS mutations were present in 14.7% of primary lesions with no increase in metastatic lesions, and did not influence outcome, but was significantly associated with endometrioid subtype, low grade and obesity. CONCLUSION: These results support that KRAS amplification and KRAS mRNA expression, both increasing from primary to metastatic lesions, are relevant for endometrial carcinoma disease progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · cited 1×
“Alterations of KRAS are considered to be an important biological factor in several cancer types (Pylayeva-Gupta et al, 2011).”
Background
Cited by
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Wong, G. S., Zhou, J., Liu, J. B., Wu, Z., Xu, X., Li, T., Xu, D., Schumacher, S. E., Puschhof, J., McFarland, J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0022-x · Cited by 266
“KRAS amplification was similarly noted in ovarian and endometrial cancers, where their presence was associated with enhanced rates of metastasis or poor survival 2,7 .”
Evidence of androgen action in endometrial and ovarian cancers
Gibson, D. A., Simitsidellis, I., Collins, F., & Saunders, P. T. K. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0551 · Cited by 73
“The authors report that mRNA expression levels and KRAS amplification were increased significantly in metastatic compared with primary lesions consistent with involvement of KRAS alterations in disease progression (Birkeland et al. 2012).”
BackgroundKauko, O., Laajala, T. D., Jumppanen, M., Hintsanen, P., Suni, V., Haapaniemi, P., Corthals, G., Aittokallio, T., Westermarck, J., & Imanishi, S. Y. (2015) · Scientific Reports · doi:10.1038/srep13099 · Cited by 61
Deciphering the ghost proteome in ovarian cancer cells by deep proteogenomic characterization
Garcia-del Rio, D. F., Derhourhi, M., Bonnefond, A., Leblanc, S., Guilloy, N., Roucou, X., Eyckerman, S., Gevaert, K., Salzet, M., & Cardon, T. (2024) · Cell Death & Disease · doi:10.1038/s41419-024-07046-1 · Cited by 7
An integrated model for predicting KRAS dependency
(2023) · doi:10.1371/journal.pcbi.1011095 · Cited by 3
Metadata
- Authors
- Birkeland, E., Wik, E., Mjøs, S., Hoivik, E. A., Trovik, J., Werner, H. M. J., Kusonmano, K., Petersen, K., Raeder, M. B., Holst, F., Øyan, A. M., Kalland, K.-H., Akslen, L. A., Simon, R., Krakstad, C., & Salvesen, H. B.
- Venue
- British Journal of Cancer
- Published
- 2012-10-25
- Volume
- 107
- Issue
- 12
- Pages
- 1997-2004
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2070515723
- Cited by
- 84
- References
- 2
- FWCI
- 6.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.